세계의 심장 매핑 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Cardiac Mapping Market was valued at USD 3.4 billion in 2024 and is estimated to grow at a CAGR of 11.3% to reach USD 10.9 billion by 2034. This robust growth is being driven by a rising number of patients diagnosed with cardiac arrhythmias, rapid innovation in mapping technologies, and increased preference for minimally invasive diagnostic procedures. Alongside these factors, growing investments in electrophysiology and expanded access to cardiovascular care-particularly in developing healthcare systems-are accelerating market development. As cardiology departments worldwide adopt new techniques for real-time visualization and accurate mapping, the demand for cardiac mapping tools is rapidly increasing. Hospitals and specialty centers are emphasizing precision-guided treatments to reduce procedural complications and improve patient outcomes.

The push toward healthcare modernization, coupled with supportive reimbursement frameworks and an uptick in global research funding, is shaping a promising future for cardiac mapping technologies across both established and emerging economies. As hospitals increasingly prioritize precision medicine and personalized treatment plans, the demand for real-time cardiac diagnostics is accelerating. Healthcare systems are investing in cutting-edge electrophysiology labs, and governments are offering financial incentives to adopt minimally invasive procedures. At the same time, public and private funding bodies are channeling resources into research aimed at improving mapping accuracy, reducing procedural risks, and developing AI-powered mapping platforms.

In 2024, the mapping catheters segment held 74% share. This segment remains strong due to growing cases of complex heart rhythm disorders and the need for high-definition electroanatomical data during minimally invasive electrophysiological procedures. High-density and multi-electrode catheter systems are rapidly becoming the gold standard as they allow physicians to collect tens of thousands of data points within moments, offering unmatched detail and accuracy. These mapping solutions support the identification and treatment of atrial fibrillation and ventricular tachycardia by facilitating more targeted and efficient ablation.

The contact cardiac mapping segment generated USD 3 billion in 2024 and is forecasted to grow at a CAGR of 11.6% through 2034. These systems provide precise electrical and anatomical readings by maintaining continuous contact with cardiac tissue, producing exceptionally clear activation and voltage maps. This level of detail is particularly crucial in diagnosing and treating complex arrhythmias that often require pinpoint accuracy. Due to their superior signal quality, contact mapping tools are widely preferred in clinical electrophysiology. Furthermore, automated cardiac mapping systems capable of tracking electrical signals in real time are enabling clinicians to shorten procedures while improving success rates in ablation therapies by detecting problematic tissue with greater accuracy.

United States Cardiac Mapping Market generated USD 1.7 billion in 2024. The market is projected to grow at a CAGR of 10.6% from 2025 to 2034. The country benefits from a highly developed healthcare infrastructure, including specialized electrophysiology labs and cardiac centers outfitted with advanced mapping systems. Leading hospitals and academic research centers routinely perform complex ablation procedures with sophisticated technologies that enhance procedural accuracy and safety. A favorable reimbursement environment and wide insurance coverage for EP treatments support high procedure volumes and facilitate quicker technology adoption.

Key players shaping the competitive landscape in the Global Cardiac Mapping Market include Medtronic, Abbott Laboratories, Johnson & Johnson, Boston Scientific, Lepu Medical, Kardium, MicroPort Scientific, APN Health, and EnChannel Medical. These companies are actively contributing to market evolution through innovation and strategic initiatives. Major cardiac mapping firms are reinforcing their market standing through a combination of innovation, clinical partnerships, and geographic expansion. These companies are investing heavily in R&D to introduce next-generation catheters with enhanced electrode designs and faster signal acquisition capabilities. Collaborations with top-tier hospitals and academic institutions are enabling real-world testing of advanced electroanatomical mapping platforms. Many players are focusing on automation and AI-integrated software to improve data analysis during ablation procedures.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Type trends
  • 2.2.4 Indication trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 High incidence of cardiovascular diseases
    • 3.2.1.2 Rising awareness about the treatment options for cardiovascular diseases
    • 3.2.1.3 Favourable government policies for research and funding
    • 3.2.1.4 Technological advancements in the products
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of the cardiac mapping systems
    • 3.2.2.2 Lack of skilled and experienced electrophysiologists
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing use of mapping systems in pediatric cardiology
    • 3.2.3.2 Increasing adoption of 3D electroanatomical mapping
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technology landscape
• 3.6 Reimbursement scenario
• 3.7 Gap analysis
• 3.8 Pricing analysis, by product, at global level, 2024
  • 3.8.1 Mapping systems
  • 3.8.2 Mapping catheters
• 3.9 Porter's analysis
• 3.10 PESTEL analysis
• 3.11 Future market trends
• 3.12 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 By Region
    • 4.3.1.1 North America
    • 4.3.1.2 Europe
    • 4.3.1.3 Asia Pacific
    • 4.3.1.4 Latin America
    • 4.3.1.5 MEA
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Mapping catheters
• 5.3 Mapping systems

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Contact cardiac mapping
• 6.3 Non-contact cardiac mapping

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Atrial fibrillation
• 7.3 Atrial flutter
• 7.4 Ventricular tachycardia
• 7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 EP labs
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 APN Health
• 10.3 Boston Scientific
• 10.4 EnChannel Medical
• 10.5 Johnson & Johnson
• 10.6 Kardium
• 10.7 Lepu Medical
• 10.8 Medtronic
• 10.9 MicroPort Scientific